CN114126712A - 无定形司巴森坦（sparsentan）组合物 - Google Patents

无定形司巴森坦（sparsentan）组合物 Download PDF

Info

Publication number
CN114126712A
CN114126712A CN201980092448.1A CN201980092448A CN114126712A CN 114126712 A CN114126712 A CN 114126712A CN 201980092448 A CN201980092448 A CN 201980092448A CN 114126712 A CN114126712 A CN 114126712A
Authority
CN
China
Prior art keywords
compound
pharmaceutical composition
amorphous
pharmaceutically acceptable
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980092448.1A
Other languages
English (en)
Chinese (zh)
Inventor
代纽斯·马奇凯纳斯
卡莱·鲁比
詹姆斯·弗朗西斯·胡尔瓦特
X·吴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Traville Treatment Co
Original Assignee
Traville Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Traville Treatment Co filed Critical Traville Treatment Co
Publication of CN114126712A publication Critical patent/CN114126712A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980092448.1A 2018-12-21 2019-12-20 无定形司巴森坦（sparsentan）组合物 Pending CN114126712A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862783947P 2018-12-21 2018-12-21
US62/783,947 2018-12-21
PCT/US2019/068094 WO2020132594A1 (en) 2018-12-21 2019-12-20 Amorphous sparsentan compositions

Publications (1)

Publication Number Publication Date
CN114126712A true CN114126712A (zh) 2022-03-01

Family

ID=69187971

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980092448.1A Pending CN114126712A (zh) 2018-12-21 2019-12-20 无定形司巴森坦（sparsentan）组合物

Country Status (12)

Country Link
US (1) US20220048900A1 (https=)
EP (1) EP3897834A1 (https=)
JP (1) JP2022514569A (https=)
KR (1) KR20210125994A (https=)
CN (1) CN114126712A (https=)
AU (1) AU2019404552A1 (https=)
BR (1) BR112021012226A2 (https=)
CA (1) CA3124127A1 (https=)
IL (1) IL284186A (https=)
MA (1) MA54542A (https=)
MX (1) MX2021007258A (https=)
WO (1) WO2020132594A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024175082A1 (zh) * 2023-02-24 2024-08-29 江苏豪森药业集团有限公司 含芳环类衍生物拮抗剂的盐、其制备方法和应用
CN118666826A (zh) * 2024-08-23 2024-09-20 成都臻拓医药科技有限公司 一种司帕生坦原料药的重结晶纯化方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53817A (fr) 2018-10-04 2021-08-11 Travere Therapeutics Inc Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv
WO2022266370A1 (en) 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
EP4458826A4 (en) * 2021-12-28 2025-12-24 Alchemedicine Inc COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044239A2 (en) * 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2010114801A1 (en) * 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
WO2010135350A2 (en) * 2009-05-20 2010-11-25 Pharmacopeia, Llc Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist
WO2018071784A1 (en) * 2016-10-13 2018-04-19 Retrophin, Inc. Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044239A2 (en) * 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2010114801A1 (en) * 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
CN104107176A (zh) * 2009-03-31 2014-10-22 利亘制药公司 治疗高血压和糖尿病肾病的二苯基磺酰胺内皮素和血管紧张素ii受体激动剂的口服制剂
WO2010135350A2 (en) * 2009-05-20 2010-11-25 Pharmacopeia, Llc Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist
WO2018071784A1 (en) * 2016-10-13 2018-04-19 Retrophin, Inc. Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIAN YU: "Amorphous pharmaceutical solids:preparation, characterization and stabilization", ADVANCED DRUG DELIVERY REVIEWS, 31 December 2001 (2001-12-31), pages 27 - 42 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024175082A1 (zh) * 2023-02-24 2024-08-29 江苏豪森药业集团有限公司 含芳环类衍生物拮抗剂的盐、其制备方法和应用
CN118666826A (zh) * 2024-08-23 2024-09-20 成都臻拓医药科技有限公司 一种司帕生坦原料药的重结晶纯化方法

Also Published As

Publication number Publication date
CA3124127A1 (en) 2020-06-25
MX2021007258A (es) 2021-08-16
US20220048900A1 (en) 2022-02-17
EP3897834A1 (en) 2021-10-27
BR112021012226A2 (pt) 2021-09-08
KR20210125994A (ko) 2021-10-19
AU2019404552A1 (en) 2021-07-15
IL284186A (en) 2021-08-31
WO2020132594A1 (en) 2020-06-25
JP2022514569A (ja) 2022-02-14
MA54542A (fr) 2021-10-27

Similar Documents

Publication Publication Date Title
CN114126712A (zh) 无定形司巴森坦（sparsentan）组合物
EP3270696B1 (en) Solid dispersions comprising ospemifene
EP2493456B1 (en) Solid dispersion of rifaximin
KR101931209B1 (ko) Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
WO2001095912A1 (fr) Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
KR20100126452A (ko) 난용성 약물용 약학적 조성물
KR20140029554A (ko) 피르페니돈 및 약학적으로 허용가능한 부형제의 캡슐 제제
JP2011516613A (ja) 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
WO2022177983A1 (en) Pharmaceutical compositions of cabozantinib
US10842751B2 (en) Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
WO2022095913A1 (en) Solid formulation
JP2018516942A (ja) 生体利用率が改善された含プランルカスト固形製剤の組成物及びその製造方法
CA3245018A1 (en) THERAPEUTIC COMPOUNDS, FORMULATIONS AND THEIR USE
AU2022338032A1 (en) Co-crystals
US20220175766A1 (en) Compositions and methods of treatment
CN105828827A (zh) 一种含他克莫司的药物组合物及其制备方法
US20250170065A1 (en) Therapeutic compounds, formulations, and use thereof
WO2022264004A1 (en) Pharmaceutical composition comprising itraconazole
HK40114875A (en) Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
EA052180B1 (ru) Терапевтические соединения, составы и их применение
WO2024214120A1 (en) Pharmaceutical compositions of nilotinib
HK40114583A (zh) Eed抑制剂固体分散体、包含其的口服制剂及其制备方法
US20220175774A1 (en) Bioavailable Oral Dosage Form Of Tyrosine-Kinase Inhibitor
HK1175114B (en) Solid dispersion of rifaximin
HK1175114A (en) Solid dispersion of rifaximin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220301

WD01 Invention patent application deemed withdrawn after publication